Doménech T, Beleta J, Palacios J M
Research Institute, Laboratorios Almirall, S.A., Cardener, Barcelona, Spain.
Naunyn Schmiedebergs Arch Pharmacol. 1997 Sep;356(3):328-34. doi: 10.1007/pl00005058.
The study of serotonin (5-HT) receptors from the points of view of their anatomical localization and pharmacological characterization has been linked to the availability of highly selective radioligands exhibiting high affinity for their targets. This is particularly so in the case of serotonin receptors, since many different subtypes with overlapping pharmacological profiles have been described. Of these, the serotonin 5-HT1 receptor family appears to be the most complex in terms of molecular diversity and pharmacological properties. The lack of appropriate tools to characterize the different receptor subtypes included in this family has hampered progress in the understanding of biological function. In the case of serotonin 5-HT1D receptors all the radioligands used so far in their characterization behave as agonists from the functional point of view. This agonistic character is regarded as a disadvantage for radioligands since their interaction with the receptors under study depends on factors other than the abundance of the receptor, such as the coupling of the receptors with G-proteins. We describe here the binding properties of [3H]-GR-125743, a new radiolabelled derivative of a compound that exhibits selective antagonistic properties with respect to the serotonin human (h5-HT1D) and human (h5-HT1B) receptors. The compound has been characterized for its ability to label the cloned h5-HT1D and h5-HT1B receptors. The binding obtained in both cases was specific, saturable and reversible, whereas the percentage of specific binding depended on the level of expression of the receptors. Using saturation analysis we have found that, on the specific clones used in this study, the compound labels a receptor population 5 to 10-fold higher that the one revealed using [3H]-5-carboxamidotryptamine, a compound with agonist properties for these receptors in functional assays. Using [3H]-GR-125743 as a radioligand we have characterized the pharmacological profile of the same cloned h5-HT1D and h5-HT1B receptor preparations for a range of serotonin reference compounds by means of displacement assays. The affinities found have been compared, using regression analysis, with those obtained for the same radioligand and compounds in membranes obtained from human substantia nigra, a tissue known to be rich in hS-HT(1B/1D) receptors. We have found a better correlation, both in terms of correlation coefficient and of slope, between the substantia nigra data and the h5-HT1B data compared with the h5-HT1D data (0.94 and 1.05 vs. 0.86 and 0.64 respectively). Finally, the addition of 100 microM GTP reduced the binding of [3H]-GR-125743 to h5-HT1D and h5-HT1B receptor subtypes by approximately 20% without affecting the affinities obtained for different displacers. Therefore, [3H]-GR-125743 appears to be a suitable radioligand for the characterization of h5-HT1D and h5-HT1B receptor subtypes, being potentially more useful than previously existing compounds.
从5-羟色胺(5-HT)受体的解剖定位和药理学特性角度进行的研究,与对其靶点具有高亲和力的高选择性放射性配体的可得性相关。5-羟色胺受体的情况尤其如此,因为已经描述了许多具有重叠药理学特征的不同亚型。其中,5-羟色胺5-HT1受体家族在分子多样性和药理学特性方面似乎最为复杂。缺乏合适的工具来表征该家族中不同的受体亚型阻碍了对其生物学功能理解的进展。就5-羟色胺5-HT1D受体而言,到目前为止用于其表征的所有放射性配体从功能角度来看都表现为激动剂。这种激动特性被认为是放射性配体的一个缺点,因为它们与所研究受体的相互作用取决于除受体丰度之外的其他因素,例如受体与G蛋白的偶联。我们在此描述了[3H]-GR-125743的结合特性,它是一种化合物的新放射性标记衍生物,对人5-羟色胺(h5-HT1D)和人(h5-HT1B)受体表现出选择性拮抗特性。该化合物已因其标记克隆的h5-HT1D和h5-HT1B受体的能力而得到表征。在这两种情况下获得的结合都是特异性的、可饱和的和可逆的,而特异性结合的百分比取决于受体的表达水平。通过饱和分析我们发现,在本研究中使用的特定克隆上,该化合物标记的受体群体比使用[3H]-5-羧酰胺色胺所揭示的受体群体高5至10倍,[3H]-5-羧酰胺色胺在功能测定中对这些受体具有激动剂特性。使用[3H]-GR-125743作为放射性配体,我们通过置换试验表征了一系列5-羟色胺参考化合物对相同克隆的h5-HT1D和h5-HT1B受体制剂的药理学特征。使用回归分析将所发现的亲和力与在从人黑质获得的膜中使用相同放射性配体和化合物所获得的亲和力进行了比较,已知人黑质富含hS-HT(1B/1D)受体。我们发现,与h5-HT1D数据相比,黑质数据与h5-HT1B数据之间在相关系数和斜率方面都有更好的相关性(分别为0.94和1.05对0.86和0.64)。最后,添加100 microM GTP使[3H]-GR-125743与h5-HT1D和h5-HT1B受体亚型的结合降低了约20%,而不影响不同置换剂获得的亲和力。因此,[3H]-GR-125743似乎是用于表征h5-HT1D和h5-HTB受体亚型的合适放射性配体,可能比先前存在的化合物更有用。